Could GATE-16 help unlock the gate to treatment response in pancreatic ductal adenocarcinoma?
Could GATE-16 help unlock the gate to treatment response in pancreatic ductal adenocarcinoma?
GATE-16 能否帮助打开胰腺导管腺癌治疗反应的大门？
批准号：
495197
负责人：
Chan Jennifer
金额：
$0.11万
依托单位国家：
加拿大
项目类别：
财政年份：
2023
资助国家：
加拿大
项目状态：
已结题
起止时间：
2023-10-01 至 2024-10-01
关键词：
中文摘要
翻译
胰腺导管腺癌（PDAC）是最常见的胰腺癌类型，占所有诊断的90%以上。快速进展，晚期诊断和耐药性是使PDAC具有侵袭性的因素之一
英文摘要
Pancreatic ductal adenocarcinoma (PDAC) is the most commonly diagnosed type of pancreatic cancer, which accounts for more than 90% of all diagnoses. Fast progression, late-stage diagnosis, and drug resistance are among factors that make PDAC an aggressive
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Using 2D and 3D models to investigate the role of GABARAPL2 in pancreatic ductal adenocarcinoma treatment response
-
批准号：466854
-
项目类别：Studentship Programs
-
资助金额：$1.27万
-
财政年份：2021
-
负责人：Chan Jennifer
-
依托单位：